Related Experiment Video
Updated: Jul 16, 2025
05:57
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
772
[Antihypertensive treatment: the winning combination]
Ella Sandoz1, Antoinette Pechère-Bertschi2
1Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue Medicale Suisse
|September 13, 2023
Summary
New 2023 hypertension guidelines recommend dual antihypertensive therapy using single pill combinations (SPCs). These SPCs simplify treatment, improve patient compliance, and enhance blood pressure control for better cardiovascular protection.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health Policy
Context:
- Hypertension management is a critical global health priority.
- Recent 2023 guidelines address hypertension control amidst a global pandemic.
- Current strategies emphasize early and effective blood pressure reduction.
Purpose:
- To outline the updated 2023 recommendations for hypertension management.
- To highlight the role of combination antihypertensive therapy.
- To discuss the benefits of single pill combinations (SPCs) in hypertension treatment.
Summary:
- The 2023 guidelines advocate initiating dual antihypertensive therapy for most patients.
- Subsequent treatment steps involve optimizing blood pressure control with additional drug classes, preferably in SPCs.
- These polypills combine multiple antihypertensive agents to improve efficacy and patient adherence.
Impact:
- SPCs offer more effective blood pressure reduction compared to monotherapy.
- Early cardioprotection is achieved through more consistent blood pressure management.
- Simplified treatment regimens and reduced adverse effects enhance patient compliance and overall outcomes.
Related Concept Videos
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
13
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
13
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:25Antihypertensive Drugs: Direct Renin Inhibitors
677
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
677
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
776
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
776
01:28Antihypertensive Drugs: Types of β-Blockers
732
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
732